Sage Journals: Discover world-class research

Abstract

Premature ejaculation (PE) is a common male sexual dysfunction. Advances in PE research have been hampered owing to a nonstandardized definition of PE, until the definition by the International Society of Sexual Medicine (ISSM) in 2009. Once the diagnosis of PE is established through a thorough history, a variety of medical therapies is available, including tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), centrally acting opiates, phosphodiesterase 5 inhibitors and topical desensitizing creams. Most of these treatments increase the intravaginal ejaculation latency time (IELT) and patient satisfaction scores, with the most convincing evidence for SSRIs and topical creams. Daily SSRIs such as paroxetine, although efficacious, do have a substantial and prolonged side effect profile. Dapoxetine, which is a on-demand SSRI, is the only licensed drug for the treatment of PE, increasing IELT by a factor of 2.5 to 3 with limited and tolerable side effects. In the near future, the topical aerosol PSD502 is due to be licensed for the treatment of PE, increasing IELT by up to a factor of 6 but having minimal local and negligible systemic side effects.

Keywords

male sexual dysfunction medical therapy medical treatment premature ejaculation

Introduction

Premature ejaculation (PE) can be a debilitating male sexual impairment. A range of studies have suggested a prevalence of 4–39% [Laumann et al. 1999; Grenier and Byers, 1995; Spector and Carey, 1990; Nathan, 1986; Reading and West, 1984]. This wide range can be partly attributed to variations in the way that PE is defined, but may also reflect differences between populations and differences in the degree of bother. Furthermore, because of the intimate nature of the problem, PE tends to be under-reported by patients who do not typically seek medical help [Grenier and Byers, 1995].

Definition of premature ejaculation

Over the years, PE has been defined in various ways. Some consider it controversial that PE is even considered to be a sexual dysfunction at all, since all male upper mammalian species, including primates ejaculate almost immediately on penetration of the vagina [Wainberg, 1984].

However, initial definitions of PE revolved around ejaculation which regularly occurs at or around initial vaginal penetration [Marmor, 1976]. A quantitative element was subsequently added to the definition. For instance, the arbitrary time of 1 minute from vaginal penetration to ejaculation was suggested by some [Marmor, 1976] while others defined the condition in terms of the number of penile thrusts (at least 15) inside the vagina before ejaculation [Colpi et al. 1986]. Other authors added a more subjective element to the definition by defining PE as ejaculation that happens prior to when the male desires it [Hastings, 1963] or ejaculations which are satisfactory to the female partner in less than 50% of sexual intercourses [Masters and Johnson, 1970]. A consensus on a standardized definition for PE was clearly needed.

Several attempts have been made over the years by a number of major societies (WHO, APA, EAU, AUA, ISSM) dealing with male sexual dysfunction to reach a consensus on the definition of PE. Table 1 illustrates the various definitions of PE.

Table 1.

Early definitions of premature ejaculation.

Organization	Definition
The World Health Organisation (WHO) (International Classification of Diseases-ICD, 1994) [WHO, 1994]	An inability to delay ejaculation sufficiently to enjoy lovemaking, which manifests as either of the following:
	• occurrence of ejaculation before or very soon after the beginning of intercourse (within 15 seconds of the beginning of intercourse)
	• occurrence of ejaculation in the absence of sufficient erection to make intercourse possible
	Exclusion criteria: PE is not the result of prolonged absence from sexual activity.
The American Psychiatric Association (APA) (The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), 2000) [APA, 2000]	• Persistent or recurrent ejaculation with minimal sexual stimulation before, on or shortly after penetration and before the person wishes it. The disturbance causes marked distress or interpersonal difficulty.
	Exclusion: PE is not due exclusively to the direct effects of a substance (e.g. withdrawal from opioids) and factors that affect duration of the excitement phase, such as age, novelty of the sexual partner or situation, and recent frequency of sexual activity.
The European Association of Urology (EAU) (Guidelines on Disorders of Ejaculation, 2001) [Colpi et al. 2001]	• The inability to control ejaculation for a sufficient length of time before vaginal penetration.
	Exclusion: Impairment of fertility does not happen when intravaginal ejaculation occurs.
The American Association of Urology (AUA) (Guidelines on the pharmacologic management of premature ejaculation, 2004) [Montague et al. 2004]	• Ejaculation that occurs sooner than desired, either before or shortly after penetration, causing distress to either one or both partners.

PE, premature ejaculation.

All of the above definitions acknowledge one or more of the three core components to PE:

a short ejaculatory latency;

a lack of control over ejaculation;

a lack of sexual satisfaction.

In 2009, the International Society of Sexual Medicine (ISSM) [Althof et al. 2009] produced its guidelines of the diagnosis and management of PE. It postulated an evidence-based definition of PE and defined PE as a male sexual dysfunction characterized by:

ejaculation which always or nearly always occurs prior to or within about 1 minute of vaginal penetration;

inability to delay ejaculation on all or nearly all vaginal penetrations;

negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual encounters.

This definition is regarded as the most robust to date owing to its evidence-based nature and has largely replaced the previous definitions as the standard definition of PE.

However, the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) due to be published in May 2013 [APA, 2013] may offer an alternative take on the definition of PE. The impact of this new definition on the diagnosis and management of PE is awaited. In the interim, the definition advocated by the authors is the ISSM's definition of PE.

Diagnosis and classification

PE can be divided into two distinct entities: acquired and lifelong PE [Godpodinoff, 1989]. Lifelong PE is a condition which has existed since the onset of sexual activity and is not reliant on either the conditions or the environment under which sexual activity is taking place. Acquired PE develops in an individual who has previously had normal ejaculatory control and can develop gradually or suddenly.

The cause of PE is usually not apparent. Some have characterized these cases as being psychogenic in origin, while others have postulated ‘biogenic’ causes [Sadeghi-Nejad and Watson, 2008]. This fundamental controversy about whether PE is behavioural or biomedical has been reflected in the two differing approaches to therapy (i.e. behavioural or psychotherapy versus pharmacological therapy). Those proposing a psychogenic basis in the absence of a definitive physical cause suggest that PE may be associated with situations such as:

anxiety;

novelty of partner or situation;

low frequency of sexual activity.

Biogenic PE is linked to an identifiable organic cause and the following conditions have been identified as possible causes:

substance abuse (e.g. alcohol);

endocrinopathy (e.g. hyperthyroidism);

chronic prostatitis;

opiate withdrawal.

Once the condition is treated, the expectation is for PE to cease.

Those who have proposed biogenic theories for the development of PE have suggested that one of the following may be the pathophysiological mechanism:

penile hypersensitivity;

hyperexcitable ejaculatory reflex;

hyperarousability;

genetic predisposition;

5-hydroxy tryptamine (5-HT)-receptor dysfunction.

Waldinger and Schweitzer introduced the concept of PE as a syndrome, with patients experiencing a continuum of symptoms [Waldinger and Schweitzer, 2006]. The four main interweaving sets of symptoms are:

short IELT, with control;

short IELT, no control;

normal IELT, no control;

normal IELT, with control.

This spectrum of symptoms can therefore include a category called ‘natural variable PE’ whereby the episodes of PE are not consistent and can be situational. This group falls under the umbrella ‘short IELT and no control’. This may represent a variation of natural ejaculatory function. Another category that stems from this syndrome is the ‘Premature-like ejaculatory function’ whereby the patients perceive that they are experiencing PE while the IELTs fall in the normal range. This falls under the umbrella ‘normal IELT and no control’.

Classification of PE is still evolving as different classification models offer different clinical and research benefits [Cahangirov et al. 2011; Chan et al. 2011; Clément et al. 2009; Waldinger and Olivier, 2005; Pattij et al. 1995].

Clinical assessment

Clinical history plays an important part in the diagnosis of PE since it is by definition a self-reported diagnosis. However, clinical assessment can be challenging owing to the nature of the problem. Patients may be embarrassed and shy when relating details of their sexual experiences and exact details are not forthcoming. It may then be useful to involve the partner in the consultation.

To elicit a diagnosis of PE, the three main components of PE (timing, control and satisfaction) should be specifically addressed. Once a diagnosis of PE is established, other related avenues that should be explored are:

the nature of the PE (lifelong or acquired);

the presence or absence of any associated erectile dysfunction (ED);

the impact of the PE on the relationship with his partner;

the impact of the PE on quality of life;

previous treatment (including over the counter medication) and response to that treatment.

Examination of the patient involves a general examination as well as a more focused examination of the genitalia outlining the scrotal contents and the penis in detail. A digital rectal examination to palpate the prostate gland is also recommended. Questionnaires such as the Index of Premature Ejaculation [Yuan et al. 2004] and the Premature Ejaculation Diagnostic Tool [Symonds et al. 2007] also have a role is evaluating PE. It must be noted that the routine use of questionnaires is not very useful, as they have a tendency to confuse the picture, especially when ED occurs concurrently. ED specific questionnaires such as the IIEF and its shorter version, IIEF-5, have been shown to further complicate the issue, especially in ED and PE trials [Ramanathan et al. 2007].

Laboratory and other physiological tests are rarely indicated. History and examination are sufficient to reach a diagnosis.

Treatment

Treatment of PE can be a real challenge for the clinician (Figure 1). This is primarily because the pathophysiology of PE is so poorly understood. Over the years multiple treatment modalities have been tried, often with initial promise. However, there are few studies on long-term efficacy and durability for most of the currently available treatment options. This article aims to provide an overview of the different treatment options available together with an assessment of the supporting evidence.

Nonmedical therapy

Psychological and behavioural therapy historically have a significant role in the management of PE.

Behavioural therapy

The ‘stop–start’ strategy (stopping coitus in situ and restarting after a delay) and its evolution to the ‘squeeze’ technique (the physical application of pressure at the base of the head of the penis) have been reported since the 1950s [Semans, 1956]. However, while short-term benefits have been reported (symptomatic benefit in 45–65%), the long-term results of treatment have not been conclusive (after 3 years of follow up, 75% of men showed no lasting improvement) [Hawton et al. 1986]. One strategy, particularly for younger men suffering from PE, is precoitus masturbation which partially desensitizes the penis and leads to a delay in ejaculation [Sadeghi-Nejad and Watson, 2008].

Psychotherapy

Psychotherapy involves educating both the male patient and the female partner. This can happen in the context of marriage/relationship counselling as well as psychosexual therapy [Hatzimouratidis et al. 2010]. Again short-term results have been promising although long-term benefits are unproven.

Medical therapy

The quest to develop an effective tablet to aid and ultimately cure PE has been ongoing for many decades [Schapiro, 1943]. A number of drugs have shown some promise in treating PE with varying degrees of success. At the present time, only one drug (dapoxetine) is licensed (in some countries only) for the treatment of PE. However, the other drugs described below can also be used, as long as the patient is fully aware that they are not licensed for the treatment of PE.

Historical agents

Alpha-adrenergic blocking agent (Phenoxybenzamine, alfusozin, terazosin) and monoamine oxidase inhibitor (Isocarboxazid, Phenelzine)

Together with monoamine oxidase (MAO) inhibitors, alpha-blockers were the first oral medication used for the treatment of PE. However, the side effects associated with the nonselective alpha-blockers limited their use. These agents are not used for PE anymore [Beretta et al. 1986; Shilon et al. 1984; Aycock, 1949]. More selective alpha-blockers such as terazosin have shown some promise in treating PE in patients suffering from concurrent lower urinary tract symptoms [Başar et al. 2005].

More recent agents

A range of drugs are currently used by clinicians for the management of PE including antidepressants, local anaesthetic agents and phosphodiesterase type 5 inhibitors.

Whether the medication is used regularly or on demand is an important consideration for patients when choosing the most appropriate drug for the treatment of their PE. An on-demand drug offers the flexibility of using the medication just prior to sexual intercourse, thereby reducing the risks of side effects associated with the drug for the rest of the time. Data so far suggest that generally speaking the benefit of on-demand dosing is inferior to the benefits seen with regular dosing. On the other hand, daily dosage allows for a more spontaneous sexual experience. Set against this, regular dosing results in greater exposure to the drug and may be associated with more pronounced side effects. Waldinger and colleagues showed that the majority of men (81%) preferred a daily regimen as opposed to an on-demand regimen [Waldinger et al. 2007]. Moreover, the stigma associated with the daily use of an antidepressant (i.e. selective serotonin reuptake inhibitors [SSRI]) may be a complicating factor in the compliance of patients to the treatment.

Tricyclic antidepressants (clomipramine)

There is evidence that continuous and on-demand dosing of clomipramine increases the IELT in patients suffering from PE [Strassberg et al. 1999; Kim and Seo, 1998; Segraves et al. 1993], with reports of improved sexual satisfaction both from patients and partners [Althof et al. 1995]. The use of clomipramine is limited by its associated side effects, mainly fatigue, dizziness, dry mouth and hypotension. During continuous dosing, the adverse event profile of clomipramine in men with PE was reported to be significantly worse than with SSRI treatment [Kim and Seo, 1998].

SSRIs unlicensed (escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline)

Serotonergic agents have been shown to be effective in the management of PE. The mechanism probably revolves around activation of the 5-HT_2C receptor which leads to a delay of ejaculation [Lue and Broderick, 2007; Waldinger et al. 1998]. The effect of SSRIs on the delay of ejaculation was first noted by Patterson when treating men with depression [Patterson, 1993]. Since then, studies have shown that the effect of SSRIs to delay ejaculation can be seen within days of the start of treatment with a plateauing of the effect within 4 weeks. In the variously reported studies the IELT is increased between twofold and eightfold with the use of SSRI.

The use of fluoxetine to treat PE was first described in 1994 by Forster [Forster, 1994] and Waldinger and colleagues conducted the first randomized, controlled trial to evaluate the use of paroxetine in treating PE [Waldinger et al. 1994]. Further work by the same research group demonstrated efficacy of a number of SSRIs (fluoxetine, fluvoxamine, paroxetine and sertraline) in the treatment of PE, although with varying efficacy and side-effect profiles [Waldinger et al. 1998]. Fluoxetine, sertraline and paroxetine increased IELT significantly whereas there was no statistical difference with fluvoxamine.

Kim and Seo demonstrated that treatment with sertraline was nearly as effective and had a lower incidence of side effects than clomipramine [Kim and Seo, 1998]. Further studies (prospective studies and randomized controlled trials) have confirmed the efficacy of sertraline in the management of PE [Balbay et al. 1998; Biri et al. 1998; Mendels, 1995]. Duloxetine [Athanasios et al. 2007] and Escitalopram [Safarinejad, 2007] have also been shown to be effective in treating PE. The efficacy and side-effects associated with SSRIs are described later (see Table 5).

Adverse effects with SSRIs are usually minor and include fatigue, yawning, mild nausea, loose stools and perspiration. They usually present at the beginning of the treatment and they tend to disappear within 2–3 weeks. There have been reports of decreased libido, mild ED and increased suicide risks with the use of SSRIs, especially long-term paroxetine [McMahon et al. 2004; Kim and Seo, 1998; Waldinger et al. 1998]. Therefore, it is important that patients are adequately counselled about the risks involved with the use of these drugs. Once patients have been started on SSRI treatment, it is essential to perform follow-up assessments to not only evaluate the efficacy of the drug but also to identify any side effects, especially regarding associated sexual dysfunction and suicide risks.

Licensed SSRI (dapoxetine)

Dapoxetine is the only licensed drug in the treatment of PE. It has been approved for treatment for the treatment of PE in New Zealand, Sweden, Austria, Finland, Germany, Spain, Italy and Portugal. National approvals and licenses in five other European countries are expected to follow. Dapoxetine is not approved for marketing in the United States.

Dapoxetine is a drug specifically developed for the on-demand treatment of PE. It has been extensively evaluated in five randomized, placebo-controlled phase III clinical trials involving more than 6000 men with PE. This is the largest and most comprehensive clinical trial programme to date for a drug therapy to treat PE. It is a short-acting SSRI designed to be taken only when needed and is taken 1–3 hours before sexual intercourse is anticipated.

There is evidence of its efficacy, its relatively mundane side effect profile and its validity as an on-demand medication [Feige et al. 2011; Hoy and Scott, 2010; Kaufman et al. 2009; McMahon et al. 2009; Giuliano et al. 2007]. However, the durability of the effects of dapoxetine has not yet been demonstrated in prospective, randomized trials since long-term follow up is not yet available [Safarinejad and Hosseini, 2006].

Table 2 summarizes the double-blind, randomized, placebo-controlled parallel trials to date looking at the use of dapoxetine for the treatment of PE [McMahon et al. 2011; Buvat et al. 2009; Kaufman et al. 2009; Patrick et al. 2009; Pryor et al. 2006]. A total of 6081 patients were randomized.

Table 2.

Treatment of premature ejaculation with dapoxetine (phase III clinical trials).

Study population (number, N)	Fold Increase in IELT	Most commonly reported side effects
1162 randomized	30 mg PRN: 3.5	Nausea
618 completed	60 mg PRN: 3.8	Dizziness
		Diarrhoea
		Headache
1067 randomized	30 mg PRN: 3.5	Nausea
858 completed	60 mg PRN: 3.8	Dizziness
		Somnolence
		Headache
		Vomiting
		Diarrhoea
		Nasopharyngitis
2614 randomized	30 mg PRN: 3.0	Nausea
1958 completed	60 mg PRN: 3.4	Headache
		Dizziness
		Diarrhoea
Patient Reported Outcome
1238 randomized	60 mg PRN	Nausea
811 completed	Statistically significant improvement in: • Personal distress related to ejaculation • Interpersonal difficulty related to ejaculation • Perceived control over ejaculation • Satisfaction with sexual intercourse	Dizziness
		Headache
		Diarrhoea
		Insomnia

IELT, intravaginal ejaculation latency time; PRN, pro re nata.

Desensitizing agents (SS Cream, benzocaine, prilocaine, lidocaine)

The use of a local anaesthetic to desensitize the penis prior to coitus has been described since the middle part of the last century [Damrau, 1963]. A number of these products are available as ‘over-the-counter’ medications and can be readily purchased online. They predominantly come in the form of creams although topical sprays are also available.

Xin and colleagues published data demonstrating that patients suffering from PE had an increased vibratory threshold on the glans penis when it was smeared with desensitizing cream (SS-Cream – herbal cream). Moreover, the effect was dose related [Xin et al. 2000]. Thereafter, the same research group performed a randomized controlled trial demonstrating an increase in IELT by eightfold when using the cream [Choi et al. 2000].

The efficacy of prilocaine–lidocaine cream (EMLA cream) and aerosol sprays have been demonstrated in prospective cohort studies [Dinsmore et al. 2007; Henry and Morales, 2003; Berkovitch et al. 1995] and in randomized, controlled trials [Carson and Wyllie, 2010; Busato and Galindo, 2004]. The optimum time of application of the EMLA cream has been shown to be 20 minutes prior to intercourse and the optimum concentration 5% [Atikeler et al. 2002]. However, topical cream can be messy to apply and requires the use of a condom to minimize the effect of the cream upon vaginal sensation.

With this in mind there has been a move to the use of aerosols which can be more discreet and patient friendly [Dinsmore et al. 2007]. An aerosol delivered combination of lidocaine–prilocaine spray for use in PE, labelled PSD 502 has been tested in two early stage clinical trials and two phase III study [Carson and Wyllie, 2010; Dinsmore and Wyllie, 2009; Dinsmore et al. 2007; Henry and Morales, 2003]. The spray forms a clear, slightly oily, odourless solution that remains adherent to the application site, with no condom required. It is easily wiped off, if necessary, before penetration and the anaesthetic penetrates the glans within 5 minutes although it is not capable of penetrating intact keratinised skin and will therefore not anaesthetize the shaft of the penis or the hands. Table 3 shows the efficacy and side effect profiles of PSD 502 in the phase III trials.

Table 3.

Treatment of PE with PSD 502 (randomized controlled trials).

Study population (number, N)	Efficacy	Side effects
300 randomized	Fold increase in IELT: 6.3	Patient
290 completed	Statistically significant improvement in:	ED
	• Distress	Burning sensation
	• Control	Partner
	• Satisfaction	Vulvovaginal burning
	• Interpersonal difficulty
256 randomized	Fold increase in IELT: 4.1	Patient
249 completed	Statistically significant improvement in:	ED
	• Ejaculatory	Hypoanaesthesia
	• Sexual satisfaction control	Headache
	• Distress	Partner
	Vulvovaginal burning

IELT, intravaginal ejaculation latency time; PE, premature ejaculation; ED, erectile dysfunction.

Desensitizing creams and sprays can cause side effects including hypoanaesthesia of the penile shaft and numbing of the vaginal vault of the partner, unless a condom is used [Lue and Broderick, 2007]. Irritating local and systemic effects have also been reported, although they are rare [Busato and Galindo, 2004; Atikeler et al. 2002].

PDE5 inhibitors (sildenafil, vardenafil, tadalafil)

The role of PDE5 inhibitors (PDE5-I) in the management of PE is controversial. Although a prospective study showed an increase of IELT of a factor of 5.7 in patients using sildenafil for the treatment of PE [Wang et al. 2007], there still is minimal evidence to propose the use of PDE5-I in treating PE. Table 4 gives a summary of the randomized, controlled trials for PDE5-I.

Table 4.

Randomized, controlled trials of PDE5-I.

Study population	Efficacy for treatment of PE	Side effects
42 randomized	Fold increase in IELT (vardenafil): 7.3	Headache
40 completed	Fold increase in IELT (placebo): 1.3	Dyspepsia
Drug: vardenafil	Statistically significant increase in:	Flushing
	• control
	• satisfication
	• distress
157 randomized	Fold increase in IELT (sildenafil): 2.6	Headache
144 completed	Fold increase in IELT (placebo): 1.6	Flushing
Drug: sildenafil	Moderate increase in patient satisfaction	Dyspepsia
		Abnormal vision
		Rhinitis

IELT, intravaginal ejaculation latency time; PE, premature ejaculation.

Table 5.

Efficacy and side effects of drugs used in the management of PE.

Drug	Dose	Usage	Side effects	Relative increase in IELT
Clomipramine	12.5–50 mg	PRN Daily dose	Fatigue	4
			Nausea
			Dizziness
			Dry mouth
			Hypotension
Unlicensed SSRI Escitalopram Fluoxetine Fluvoxamine Paroxetine Sertraline	20–40 mg 20–40 mg 25–50 mg 10–40 mg 50–200 mg	Daily dose	Fatigue
			Nausea	2
			Diarrhoea	5
			Yawning	1.5
			Diaphoresis	8
			ED	5
			Decreased libido

Dapoxetine (licensed SSRI)	30–60 mg	PRN	Nausea	2.5–3.0
Dapoxetine (licensed SSRI)			Diarrhoea
			Headache
			Dizziness
Desensitizing agents EMLA SS Cream TEMPE (PSD502)	Smear	PRN	Messy Numbing of the vagina Skin irritation ED	4–8
Desensitizing agents EMLA SS Cream TEMPE (PSD502)	Smear Spray		Messy Numbing of the vagina Skin irritation ED
PDE5-I Vardenafil	10 mg		PRN	Headache	3
				Flushing
				Nausea
Tramadol	50 mg	PRN	Dizziness	3.6–7.0
			Drowsiness
			Nausea
			Constipation

IELT, intravaginal ejaculation latency time; PE, premature ejaculation; ED, erectile dysfunction; SSRI, selective serotonin reuptake inhibitor; PRN, pro re nata.

Epidemiological studies have shown that a third of men with ED suffer from PE [Corona et al. 2004]. This association between PE and ED may be explained by the fact that when a man suffers from ED, he makes a compensatory effort to achieve ejaculation before the loss of the erection, leading to PE. A possible carry on effect from this is when the man suffering from ED tries to overstimulate himself to achieve a rigid erection, whereby this overstimulation leads to PE [Jannini et al. 2005]. Therefore, by treating the ED with PDE5 inhibitors, the corresponding associated PE improves. However, evidence that this mechanism is actually occurring is not forthcoming as yet. There are just two randomized controlled trials evaluating a PDE5-I in the management of PE [Aversa et al. 2009; McMahon et al. 2005].

Although the evidences does not strongly support the use of PDE5-I in primary PE, it may have a role in treating PE in patients intolerant to dapoxetine, especially if the PE is associated with ED.

Centrally acting opioid analgesic (tramadol)

Safarinejad and Hosseini have published a randomized, controlled trial on the use of tramadol HCL to treat PE [Safarinejad and Hosseini, 2006]. Various research groups have shown tramadol to have some efficacy in treating PE [Alghobary et al. 2010], especially as an on-demand medication, although the mechanism is poorly understood [Alghobary et al. 2010; Salem et al. 2008; Safarinejad and Hosseini, 2006]. However, there is evidence that some cases of secondary PE are seen in men who are withdrawing from opiate addiction. There may therefore be a relation between central opioid receptors and ejaculatory control.

Table 5 gives a summary of the medication currently being used for the treatment of PE.

Future possibilities

Additional research is required to eventually develop a product which is acceptable to the patient by being effective all of the time with minimal side effects and that is easy and discreet to use without compromising spontaneity during sexual intercourse. Some of the possibilities are as follows:

9-hydroxycanthin-6-one (9-HC-6-one), a β-carboline alkaloid isolated from Eurycoma longifolia. In vitro, it has been noted that 9-HC-6-one attenuated PE-induced contraction by blocking calcium channels [Chiou and Wu, 2011].

It has been noted that decreased levels of magnesium may give rise to vasoconstriction from an increased thromboxane level, increased endothelial intracellular Ca2+, and decreased nitric oxide. This mechanism has been attributed to PE [Mohammadreza et al. 2009].

However, there is a long way to go before these products can be marketed. Moreover, reproducible in vitro and in vivo studies are required and the formulation of a standardized definition of PE is possibly the first building block towards standardization of PE research.

Conclusion

PE is a common condition affecting around one in five men. It can be a cause of significant personal distress which may in turn affect the relationship of the man with his partner. While many men with PE do not seek medical attention, when they do, SSRIs, desensitizing creams and to a lesser extent PDE5-I have been used in the treatment. All of these medications are sold off-label for the treatment of PE except for the recently licensed dapoxetine (Priligy^TM) which provides an effective, on-demand treatment regimen with relatively minimal side effects. PSD 502 is currently in the development phase and with the conclusion of phase III trials, may soon be licensed as a topical aerosolised spray for the treatment of PE.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Figure 1.

Management of premature ejaculation. PE, premature ejaculation; ED, erectile dysfunction.

Conflict of interest statement

The authors declare no conflicts of interest in preparing this article.

References

Alghobary

M.M.D.

El-Bayoumy

Y.M.D.

Mostafa

Y.M.D.

Mahmoud

E.-H.M.M.D.

Amr

M.M.D.

(2010) Evaluation of tramadol on demand vs. daily paroxetine as a long-term treatment of lifelong premature ejaculation. J Sexual Med 7: 2860–2867.

Althof, S., Abdo, C., Dean, J., Hackett, G., McCabe, M., McMahon, C. et al. (2009) International Society for Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation. http://www.issm.info/v4/. Accessed on 23 September 2011.

Althof

Levine

Corty

Risen

Stern

Kurit

(1995) A double-blind crossover trial of clomipramine for rapid ejaculation in 15 couples. J Clin Psychiatry 56: 402–407.

APA. (2000) Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association.

APA (2013) Diagnostic and Statistical Manual of Mental Disorders Development, 5^th edition (DSM-5). Available at: http://www.dsm5.org/proposedrevision/pages/proposedrevision.aspx?rid=174# (Accessed September 2011).

Athanasios

Polyanthi

George

(2007) The efficacy of duloxetine in the treatment of premature ejaculation. Int Urol Nephrol 39: 115–118.

Atikeler

Gecit

Senol

(2002) Optimum usage of prilocaine-lidocaine cream in premature ejaculation. Andologia 34: 356–359.

Aversa

Pili

Francomano

Bruzziches

Spera

La Pera

(2009) Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. Int J Impot Res 21: 221–227.

Aycock

(1949) The medical management of premature ejaculation. J Urol 62: 361–361.

10.

Balbay

Yildiz

Şalvarci

Özsan

Ö.

Özbek

(1998) Treatment of premature ejaculation with sertralin. Int Urol Nephrol 30: 81–83.

11.

Başar

Yılmaz

Ferhat

Başar

Batislam

(2005) Terazosin in the treatment of premature ejaculation: a short-term follow-up. Int Urol Nephrol 37: 773–777.

12.

Beretta

Chelo

Fanciullacci

Zanollo

(1986) Effect of an alpha-blocking agent (phenoxybenzamine) in the management of premature ejaculation. Acta Eur Fertil 17: 43–45.

13.

Berkovitch

Keresteci

Koren

(1995) Efficacy of prilocaine-lidocaine cream in the treatment of premature ejaculation. J Urol 154: 1360–1361.

14.

Biri

Isen

Sinik

Onaran

Küpeli

Bozkirli

(1998) Sertraline in the treatment of premature ejaculation: A double-blind placebo controlled study. Int Urol Nephrol 30: 611–615.

15.

Busato

Galindo

C.C.

(2004) Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebo-controlled study. BJU Int 93: 1018–1021.

16.

Buvat

Tesfaye

Rothman

Rivas

D.A.

Giuliano

(2009) Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 55: 957–968.

17.

Cahangirov

Cihan

Murat

Demir

Aslan

Gidener

(2011) Investigation of the neural target level of hyperthyroidism in premature ejaculation in a rat model of pharmacologically induced ejaculation. J Sexual Med 8: 90–96.

18.

Carson

Wyllie

(2010) Improved ejaculatory latency, control and sexual satisfaction when PSD502 is applied topically in men with premature ejaculation: results of a phase III, double-blind, placebo-controlled study. J Sex Med 7: 3179–3189.

19.

Chan

J.S.W.

Snoeren

E.M.S.

Cuppen

Waldinger

M.D.

Olivier

Oosting

R.S.

(2011) The serotonin transporter plays an important role in male sexual behavior: a study in serotonin transporter knockout rats. J Sexual Med 8: 97–108.

20.

Chiou

W.-F.

T.-S.

(2011) 9-Hydroxycanthin-6-one induces penile erection and delays ejaculation. J Sexual Med DOI: 10.1111/j.1743-6109.2011.02296.x.

21.

Choi, H.K., Jung, G.W., Moon, K.H., Xin, Z.C., Choi, Y.D., Lee, W.H. et al. (2000) Clinical study of SS-cream in patients with lifelong premature ejaculation1 1 SS-cream was developed originally by Drs. H. K. Choi and Z. C. Xin in Korea. The drug was supported and sponsored by the research fund of Cheil Jedang Co. in Seoul, Korea. All authors have financial interests and other relationships with SS-cream. Urology 55: 257–261.

22.

Clément

Pozzato

Heidbreder

Alexandre

Giuliano

Melotto

(2009) Delay of Ejaculation Induced by SB-277011, a selective dopamine D3 receptor antagonist, in the rat. J Sexual Med 6: 980–988.

23.

Colpi

G.M.

Fanciullacci

Beretta

Negri

Zanollo

(1986) Evoked sacral potentials in subjects with true premature ejaculation. Andrologia 18: 583–586.

24.

Colpi, G. M., Hargreave, T.B., Papp, G. K., Pomerol, J. M. and Weidner, W. (2001) Guidelines on disorders of ejaculation. European Association of Urology. Available at: http://www.uroweb.org/fileadmin/user_upload/Guidelines/2001_Disorders_of_ Ejaculation.PDF.

25.

Corona

Petrone

Mannucci

Jannini

E.A.

Mansani

Magini

(2004) Psycho-biological correlates of rapid ejaculation in patients attending an andrologic unit for sexual dysfunctions. Eur Urol 46: 615–622.

26.

Damrau

(1963) Premature ejaculation: Use of ethyl aminobenzoate to prolong coitus. J Urol 89: 936–936.

27.

Dinsmore

W.W.

Hackett

Goldmeier

Waldinger

Dean

Wright

(2007) Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int 99: 369–375.

28.

Dinsmore

W.W.

Wyllie

M.G.

(2009) PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study. BJU Int 103: 940–949.

29.

Feige

A.M.

Pinsky

M.R.

Hellstrom

W.J.

(2011) Dapoxetine for Premature Ejaculation. Clin Pharmacol Therapeut 89: 125–128.

30.

Forster

(1994) Fluoxetine for premature ejaculation. Am J Psychiatry 151: 1523–1523.

31.

Giuliano

Bernabe

Gengo

Alexandre

Clement

(2007) Effect of acute dapoxetine administration on the pudendal motoneuron reflex in anesthetized rats: comparison with paroxetine. J Urol 177: 386–389.

32.

Godpodinoff

(1989) Premature ejaculation: clinical subgroups and etiology. J Sex Marital Ther 15: 693–705.

33.

Grenier

Byers

(1995) Rapid ejaculation: A review of conceptual, etiological, and treatment issues. Arch Sex Behav 24: 447–472.

34.

Hastings

(1963) Impotence and Frigidity Boston, MA: Little Brown & Co.

35.

Hatzimouratidis

Amar

Eardley

Giuliano

F.H.D.

Montorsi

(2010) Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. Eur Urol in press.

36.

Hawton

Catalan

Martin

Fagg

(1986) Long-term outcome of sex therapy. Behav Res Therapy 24: 665–675.

37.

Henry

Morales

(2003) Topical lidocaine-prilocaine spray for the treatment of premature ejaculation: a proof of concept study. Int J Impot Res 15: 277–281.

38.

Hoy

S.M.

Scott

L.J.

(2010) Dapoxetine: in premature ejaculation. Drugs 70: 1433–1443.

39.

Jannini

E.A.

Lombardo

Lenzi

(2005) Correlation between ejaculatory and erectile dysfunction. Int J Androl 28: 40–45.

40.

Kaufman

J.M.

Rosen

R.C.

Mudumbi

R.V.

Tesfaye

Hashmonay

Rivas

(2009) Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU Int 103: 651–658.

41.

Kim

S.C.

Seo

K.K.

(1998) Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol 159: 425–427.

42.

Laumann

Paik

Rosen

(1999) Sexual dysfunction in the United States: Prevalence and predictors. JAMA 281: 537–544.

43.

Lue

Broderick

Walsh

Retik

Vaughan

Wein

Kavoussi

Novick

(2007) Evaluation and nonsurgical management of erectile dysfunction and premature ejaculation. Campbell-Walsh Urology Vol. 1, Philadelphia, PA: Saunders-Elsevier, 750–787.

44.

Marmor

Sadock

Kaplan

Freedman

(1976) Impotence and ejaculatory disturbances. Sexual Experience Baltimore, MD: The Williams & Wilkins Co, 407–410.

45.

Masters

Johnson

(1970) Himan Sexual Inadequacy Boston, MA: Little, Brown & Co.

46.

McMahon

Althof

Kaufman

Buvat

Aquilina

Rivas

(2009) Efficacy and safety of dapoxetine for premature ejaculation: integrated analysis of 5 phase 3 trials: PD-068. J Sexual Med 6(Suppl. 2): 69–70.

47.

McMahon

Kim

S.W.

Park

N.C.

Chang

C.-p.

Rivas

Tesfaye

(2011) Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. J Sexual Med 7: 256–268.

48.

McMahon

C.G.

Abdo

Incrocci

Perelman

Rowland

Waldinger

(2004) Disorders of orgasm and ejaculation in men. J Sexual Med 1: 58–65.

49.

McMahon

C.G.

Stuckey

B.G.A.

Andersen

Purvis

Koppiker

Haughie

(2005) Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sexual Med 2: 368–375.

50.

Mendels

(1995) Sertraline for premature ejaculation. J Clin Psychiatry 56: 591–591.

51.

Mohammadreza

Mehdi

Mohammad

(2009) Seminal plasma magnesium and premature ejaculation: a case-control study. Urol J 2: 102–105.

52.

Montague

D.K.

Jarow

Broderick

G.A.

Dmochowski

R.R.

Heaton

J.P.

Lue

T.F.

(2004) Premature Ejaculation: Guideline on the pharmacologic management of premature ejaculation. J Urol 172: 290–294.

53.

Nathan

(1986) The epidemiology of the DSM-III psychosexual dysfunctions. J Sex Marital Ther 12: 267–281.

54.

Patrick

D.L.

Giuliano

K.F.

Gagnon

D.D.

McNulty

Rothman

(2009) The Premature Ejaculation Profile: validation of self-reported outcome measures for research and practice. BJU Int 103: 358–364.

55.

Patterson

(1993) Fluoxetine induced sexual dysfunction (letter). Clin Psychiatry 54: 71–71.

56.

Pattij

Olivier

Waldinger

M.D.

(1995) Animal models of ejaculatory behavior. Curr Pharm Des 11: 4069–4077.

57.

Pryor

J.L.

Althof

S.E.

Steidle

Rosen

R.C.

Hellstrom

W.J.G.

Shabsigh

(2006) Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 368: 929–937.

58.

Ramanathan

Mulhall

Rao

Leung

Martinez Salamanca

J.I.

Mandhani

(2007) Predictive correlation between the International Index of Erectile Function (IIEF) and Sexual Health Inventory for Men (SHIM): implications for calculating a derived SHIM for clinical use. J Sexual Med 4: 1336–1344.

59.

Reading

West

(1984) An analysis of self-reported sexual behavior in a sample of normal males. Arch Sex Behav 13: 69–83.

60.

Sadeghi-Nejad

Watson

(2008) Continuing medical education: premature ejaculation: current medical treatment and new directions (CME). J Sexual Med 5: 1037–1050.

61.

Safarinejad

M.R.M.D.

(2007) Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol 27: 444–450.

62.

Safarinejad

M.R.M.D.

Hosseini

S.Y.M.D.

(2006) Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol 26: 27–31.

63.

Salem

E.A.

Wilson

S.K.

Bissada

N.K.

Delk

J.R.

Hellstrom

W.J.

Cleves

M.A.

(2008) ORIGINAL RESEARCH–EJACULATORY DISORDERS: Tramadol HCL has promise in on-demand use to treat premature ejaculation. J Sexual Med 5: 188–193.

64.

Schapiro

(1943) Premature ejaculation: A review of 1130 cases. J Urol 50: 374–374.

65.

Segraves

Saran

Segraves

Maguire

(1993) Clomipramine versus placebo in the treatment of premature ejaculation: a pilot study. J Sex Marital Ther 19: 198–200.

66.

Semans

(1956) Premature ejaculation: a new approach. South Med J 49: 4–4.

67.

Shilon

Paz

Homonnai

(1984) The use of phenoxybenzamine treatment in premature ejaculation. Fertil Steril 42: 659–661.

68.

Spector

Carey

(1990) Incidence and prevalence of the sexual dysfunctions: A critical review of the empirical literature. Arch Sex Behav 19: 389–408.

69.

Strassberg

Brazao

C.d.G.

Rowland

Tan

Slob

(1999) Clomipramine in the treatment of rapid (premature) ejaculation. J Sex Marital Ther 25: 89–101.

70.

Symonds

Perelman

M.A.

Althof

Giuliano

Martin

May

(2007) Development and validation of a premature ejaculation diagnostic tool. Eur Urol 52: 565–573.

71.

Wainberg

Buvat

Jouaunnet

(1984) Essai d'interpretation ontogenetique de l'ejaculation prematuree. L'ejaculation et ses perturbances Simep: Lyon-Villeurbanne, 112–116.

72.

Waldinger

Hengeveld

Zwinderman

Olivier

(1998) Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol 18: 274–281.

73.

Wainberg, J. (1984) Essai d'interpretation ontogenetique de l'ejaculation prematuree., In: Buvat, J. and Jouaunnet, P., (eds), L'ejaculation et ses perturbances. Lyon-Villeurbanne: Simep, pp. 112–116.

74.

Waldinger

M.D.

Olivier

(2005) Animal models of premature and retarded ejaculation. World J Urol 23: 115–118.

75.

Waldinger

M.D.

Schweitzer

D.H.

(2006) Changing paradigms from a historical DSM-III and DSM-IV view toward an evidence-based definition of premature ejaculation. Part II—Proposals for DSM-V and ICD-11. J Sexual Med 3: 693–705.

76.

Waldinger

M.D.

Zwinderman

A.H.

Olivier

Schweitzer

D.H.

(2007) The majority of men with lifelong premature ejaculation prefer daily drug treatment: an observation study in a consecutive group of Dutch men. J Sexual Med 4: 1028–1037.

77.

Wang

W.-F.

Wang

Minhas

Ralph

D.J.

(2007) Can sildenafil treat primary premature ejaculation? A prospective clinical study. Int J Urol 14: 331–335.

78.

WHO (1994) World Health Organization International classification of diseases and related health problems. Geneva: World Health Organization.

79.

Xin

Z.C.

Choi

Y.D.

Lee

W.H.

Choi

Y.J.

Yang

W.J.

Choi

H.K.

(2000) Penile vibratory threshold changes with various doses of SS-cream in patients with primary premature ejaculation. Yonsei Med J 41: 29–33.

80.

Yuan

Y.M.

Xin

Z.C.

Jiang

Guo

Y.J.

Liu

W.J.

Tian

(2004) Sexual function of premature ejaculation patients assayed with Chinese Index of Premature Ejaculation. Asian J Androl 6: 121–126.

Medical therapy for premature ejaculation

Abstract

Keywords

Introduction

Definition of premature ejaculation

Diagnosis and classification

Clinical assessment

Treatment

Nonmedical therapy

Behavioural therapy

Psychotherapy

Medical therapy

Historical agents

Alpha-adrenergic blocking agent (Phenoxybenzamine, alfusozin, terazosin) and monoamine oxidase inhibitor (Isocarboxazid, Phenelzine)

More recent agents

Tricyclic antidepressants (clomipramine)

SSRIs unlicensed (escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline)

Licensed SSRI (dapoxetine)

Desensitizing agents (SS Cream, benzocaine, prilocaine, lidocaine)

PDE5 inhibitors (sildenafil, vardenafil, tadalafil)

Centrally acting opioid analgesic (tramadol)

Future possibilities

Conclusion

Funding

Conflict of interest statement

References